111 related articles for article (PubMed ID: 2809219)
21. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S; Darrow TL; Vervaert CE; Seigler HF
Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
[TBL] [Abstract][Full Text] [Related]
23. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
[TBL] [Abstract][Full Text] [Related]
25. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice.
Yang G; Tan J; Wei G; Deng Y; Chen H; Yang D
Transpl Immunol; 2006 Nov; 16(3-4):166-71. PubMed ID: 17138049
[TBL] [Abstract][Full Text] [Related]
26. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
[TBL] [Abstract][Full Text] [Related]
27. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
28. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
Beaujean F; Bernaudin F; Kuentz M; Lemerle S; Cordonnier C; Le Forestier C; Reinert P; Duedari N; Brandely M; Vernant JP
Bone Marrow Transplant; 1995 May; 15(5):691-6. PubMed ID: 7670397
[TBL] [Abstract][Full Text] [Related]
29. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
30. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
32. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 in autologous bone marrow transplantation.
Charak BS
Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
[TBL] [Abstract][Full Text] [Related]
34. Role of lymphokine-activated killer cells as mediators of veto and natural suppression.
Azuma E; Kaplan J
J Immunol; 1988 Oct; 141(8):2601-6. PubMed ID: 3171179
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
[TBL] [Abstract][Full Text] [Related]
36. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
37. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
38. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
39. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
Yaron I; Zakheim AR; Oluwole SF; Hardy MA
Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
[No Abstract] [Full Text] [Related]
40. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]